[go: up one dir, main page]

DE69940439D1 - Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe - Google Patents

Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe

Info

Publication number
DE69940439D1
DE69940439D1 DE69940439T DE69940439T DE69940439D1 DE 69940439 D1 DE69940439 D1 DE 69940439D1 DE 69940439 T DE69940439 T DE 69940439T DE 69940439 T DE69940439 T DE 69940439T DE 69940439 D1 DE69940439 D1 DE 69940439D1
Authority
DE
Germany
Prior art keywords
imports
streptococcus pneumoniae
immunogenic fragments
pneumoniae proteins
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940439T
Other languages
English (en)
Inventor
Leslie S Johnson
Scott Koenig
John E Adamou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22347343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69940439(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by MedImmune LLC filed Critical MedImmune LLC
Application granted granted Critical
Publication of DE69940439D1 publication Critical patent/DE69940439D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69940439T 1998-12-21 1999-12-21 Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe Expired - Lifetime DE69940439D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11304898P 1998-12-21 1998-12-21
PCT/US1999/030390 WO2000037105A2 (en) 1998-12-21 1999-12-21 Streptococcus pneumoniae proteins and immunogenic fragments for vaccines

Publications (1)

Publication Number Publication Date
DE69940439D1 true DE69940439D1 (de) 2009-04-02

Family

ID=22347343

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940439T Expired - Lifetime DE69940439D1 (de) 1998-12-21 1999-12-21 Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe

Country Status (12)

Country Link
US (5) US6582706B1 (de)
EP (2) EP2050464B1 (de)
JP (1) JP4689044B2 (de)
AT (1) ATE422899T1 (de)
AU (1) AU776828B2 (de)
CA (1) CA2355364C (de)
CY (1) CY1109024T1 (de)
DE (1) DE69940439D1 (de)
DK (1) DK1140157T3 (de)
ES (1) ES2322306T3 (de)
PT (1) PT1140157E (de)
WO (1) WO2000037105A2 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2277362T5 (es) * 1996-10-31 2014-12-18 Human Genome Sciences, Inc. Antígenos y vacunas de streptococcus pneumoniae
US6676943B1 (en) 1997-04-24 2004-01-13 Regents Of The University Of Minnesota Human complement C3-degrading protein from Streptococcus pneumoniae
US7115731B1 (en) 1997-07-02 2006-10-03 sanofi pasteur limited/ sanofi pasteur limiteé Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
KR100771148B1 (ko) 1998-02-20 2007-10-29 아이디 바이오메디칼 코포레이션 그룹 ｂ 스트렙토코커스 항원
IL138798A0 (en) * 1998-04-07 2001-10-31 Medimmune Inc Vaccines and antibodies against bacterial pneumococcal infection
DK1098980T3 (da) 1998-07-22 2014-09-29 Stichting Dienst Landbouwkundi Streptococcus suis-vacciner og diagnostiske tests
US20030134407A1 (en) 1998-07-27 2003-07-17 Le Page Richard William Falla Nucleic acids and proteins from Streptococcus pneumoniae
EP1801218A3 (de) * 1998-07-27 2007-10-10 Sanofi Pasteur Limited Nukleinsäuren und Proteine aus Pneumokokken
US7128918B1 (en) * 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
EP1950302B1 (de) 1998-12-23 2012-12-05 ID Biomedical Corporation of Quebec Streptokokken-Antigene
KR101170203B1 (ko) * 1998-12-23 2012-07-31 아이디 바이오메디칼 코포레이션 신규한 스트렙토코커스 항원
MY125387A (en) * 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
US6887480B1 (en) * 1999-06-10 2005-05-03 Medimmune, Inc. Streptococcus pneumoniae proteins and vaccines
EP1290019A2 (de) * 2000-06-14 2003-03-12 Cytovax Biotechnologies Inc. Verwendung von coiled-coil strukturmatrizen zur erzeugung von peptiden mit einer spezifischen struktur
CN101260149B (zh) * 2000-06-20 2016-05-11 魁北克益得生物医学公司 链球菌抗原
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
WO2002061070A2 (en) 2001-02-02 2002-08-08 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Environmentally regulated genes, involved in the virulence of streptococcus suis
EP1456231A2 (de) 2001-12-20 2004-09-15 Shire Biochem Inc. Streptococcus antigene
US8229903B2 (en) * 2002-12-19 2012-07-24 International Business Machines Corporation Suggesting data interpretations and patterns for updating policy documents
SI1896063T1 (sl) 2005-06-27 2012-03-30 Glaxosmithkline Biolog Sa Imunogeni sestavek
EP1754717A1 (de) 2005-08-19 2007-02-21 Université de Lausanne Antigene Peptide und deren Verwendungen
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EA014107B1 (ru) * 2005-12-22 2010-10-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP2066344B2 (de) 2006-09-07 2016-06-29 GlaxoSmithKline Biologicals S.A. Inaktiviertes Poliovirus Mischimpfstoff
BRPI0810211A2 (pt) 2007-04-13 2014-10-21 Univ Oklahoma Citolisina dependente de colesterol mutante purficada, composição, vacina, método para vacinar um paciente, anticorpo monoclonal, ácido nucléico, e, célula hospedeira.
EA201490303A1 (ru) 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
PT2167121E (pt) 2007-06-26 2015-12-02 Glaxosmithkline Biolog Sa Vacina compreendendo conjugados de polissacáridos capsulares de streptococcus pneumoniae
ES2397488T3 (es) 2007-07-23 2013-03-07 Sanofi Pasteur Limited Polipéptidos inmunógenos y anticuerpos monoclonales
US20160228500A9 (en) * 2007-07-23 2016-08-11 Martina Ochs Immunogenic Polypeptides and Monoclonal Antibodies
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2023143A1 (de) * 2007-08-06 2009-02-11 Boehringer Ingelheim Vetmedica Gmbh Immunogene Streptokokkus-Proteine
SI2268618T1 (sl) 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
ES2553113T3 (es) * 2008-04-16 2015-12-04 Glaxosmithkline Biologicals S.A. Vacuna
EP2349209A2 (de) 2008-09-26 2011-08-03 Nanobio Corporation Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür
CA2756533A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
US9517263B2 (en) 2009-06-10 2016-12-13 Glaxosmithkline Biologicals Sa Benzonaphthyridine-containing vaccines
MX2012002723A (es) 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
ES2670576T3 (es) 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
SG10201501980SA (en) 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
KR20120107121A (ko) * 2009-12-22 2012-09-28 사노피 파스퇴르 리미티드 면역원성 조성물
WO2011075822A1 (en) 2009-12-22 2011-06-30 Sanofi Pasteur Limited Immunogenic compositions and related methods
GB201003920D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
KR101853513B1 (ko) 2010-03-23 2018-04-30 노파르티스 아게 감염, 염증, 호흡기 질환 등의 치료를 위해 사용되는 ｔｌｒ2 효능제로서의 화합물 (시스테인 기재 리포펩티드) 및 조성물
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
MX2013006255A (es) 2010-12-03 2015-08-05 Sanofi Pasteur Ltd Composicion para inmunizacion contra streptococcus pneumoniae.
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
JP2014515035A (ja) * 2011-05-17 2014-06-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ストレプトコッカス・ニューモニエに対するワクチン
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
WO2014118305A1 (en) 2013-02-01 2014-08-07 Novartis Ag Intradermal delivery of immunological compositions comprising toll-like receptor agonists
EP4272750A3 (de) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Proteinantigene zum schutz gegen pneumokokkenkolonisation und/oder -befall
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX371453B (es) 2014-01-21 2020-01-29 Pfizer Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
RU2771293C2 (ru) 2014-01-21 2022-04-29 Пфайзер Инк. Иммуногенные композиции, содержащие конъюгированные капсульные сахаридные антигены, и их применение
PL3096783T3 (pl) 2014-01-21 2021-12-13 Pfizer Inc. Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
JP2017505792A (ja) 2014-02-14 2017-02-23 ファイザー・インク 免疫原性糖タンパク質コンジュゲート
FI3220937T3 (fi) 2014-11-21 2024-11-29 Univ Oklahoma Pneumolysiinimutantteja ja menetelmiä niiden käyttämiseksi
MX2017009308A (es) 2015-01-15 2017-11-08 Pfizer Composiciones inmunogenicas para usar en vacunas neumococicas.
TWI720448B (zh) 2015-07-21 2021-03-01 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composições imunogênicas para uso em vacinas pneumococais
SG11202007688YA (en) 2018-02-12 2020-09-29 Inimmune Corp Toll-like receptor ligands
MX2021000548A (es) 2018-07-19 2021-07-02 Glaxosmithkline Biologicals Sa Procesos para preparar polisacáridos en seco.
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
EP3952906A1 (de) 2019-04-10 2022-02-16 Pfizer Inc. Immunogene zusammensetzungen mit konjugierten kapselförmigen saccharidantigenen, kits damit und verwendungen davon
JP2022542316A (ja) 2019-07-31 2022-09-30 サノフィ パスツール インコーポレイテッド 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物およびその使用方法
CN114667343A (zh) 2019-11-01 2022-06-24 辉瑞大药厂 大肠杆菌组合物及其方法
CA3171864A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
PE20230170A1 (es) 2020-02-23 2023-02-01 Pfizer Composiciones de escherichia coli y sus metodos
EP4232593A1 (de) 2020-10-22 2023-08-30 Pfizer Inc. Verfahren zur reinigung von bakteriellen polysacchariden
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
EP4240841A1 (de) 2020-11-04 2023-09-13 Eligo Bioscience Aus phagen gewonnene partikel zur in-situ-abgabe von dna-nutzlast in eine c. acnes-population
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
EP4333879A1 (de) 2021-05-03 2024-03-13 Pfizer Inc. Impfung gegen bakterielle und betacoronavirus-infektionen
JP2024521847A (ja) 2021-05-28 2024-06-04 ファイザー・インク コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
PH12023553205A1 (en) 2021-05-28 2024-02-19 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4463186A1 (de) 2022-01-13 2024-11-20 Pfizer Inc. Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
KR20250008122A (ko) 2022-05-11 2025-01-14 화이자 인코포레이티드 보존제를 갖는 백신 제형의 제조 방법
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6042838A (en) * 1991-02-15 2000-03-28 Uab Research Foundation immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA)
US5928900A (en) 1993-09-01 1999-07-27 The Rockefeller University Bacterial exported proteins and acellular vaccines based thereon
CA2253252A1 (en) 1996-05-01 1997-11-06 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
EP0912193A4 (de) 1996-06-21 2000-11-02 Univ Virginia Commonwealth Impfstoff zur verhütung von streptokokken endocarditis
ES2277362T5 (es) * 1996-10-31 2014-12-18 Human Genome Sciences, Inc. Antígenos y vacunas de streptococcus pneumoniae
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
AU9510598A (en) * 1997-09-24 1999-04-12 American Cyanamid Company Human complement c3-degrading proteinase from (streptococcus pneumoniae)
DE69935986D1 (de) * 1998-07-27 2007-06-14 Sanofi Pasteur Ltd Streptococcus pneumoniae proteine und nukleinsäuren
JP2002526082A (ja) 1998-09-24 2002-08-20 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ストレプトコッカス・ニューモニア由来のヒト補体ｃ３分解ポリペプチド
KR101170203B1 (ko) * 1998-12-23 2012-07-31 아이디 바이오메디칼 코포레이션 신규한 스트렙토코커스 항원

Also Published As

Publication number Publication date
PT1140157E (pt) 2009-05-06
ATE422899T1 (de) 2009-03-15
EP2050464A3 (de) 2012-04-25
CA2355364C (en) 2014-03-18
EP2050464B1 (de) 2019-08-07
US20070065458A1 (en) 2007-03-22
US20040052781A1 (en) 2004-03-18
WO2000037105A2 (en) 2000-06-29
JP4689044B2 (ja) 2011-05-25
ES2322306T3 (es) 2009-06-18
WO2000037105A3 (en) 2000-11-09
EP1140157B1 (de) 2009-02-18
US20040001836A1 (en) 2004-01-01
JP2002532561A (ja) 2002-10-02
EP1140157A2 (de) 2001-10-10
CY1109024T1 (el) 2014-07-02
AU2373100A (en) 2000-07-12
US6582706B1 (en) 2003-06-24
EP2050464A2 (de) 2009-04-22
CA2355364A1 (en) 2000-06-29
DK1140157T3 (da) 2009-06-08
US20040005331A1 (en) 2004-01-08
AU776828B2 (en) 2004-09-23
US7122194B2 (en) 2006-10-17

Similar Documents

Publication Publication Date Title
DE69940439D1 (de) Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
ATE325620T1 (de) Streptococcus pneumoniae proteine und impfstoffe
ATE239491T1 (de) Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
NO990560L (no) Kjemisk modifiserte polypeptider
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
MY106315A (en) Pharmaceutical agents
HK184896A (en) Pharmaceutical composition comprising loratadine ibuprofen and pseudoephedrine
TR200200938T2 (tr) CCR5 modülatörleri olarak piperidinler
DK0842934T3 (da) 5-HT1F agonister
ATE279940T1 (de) Behandlung und prävention von helicobacter- infektionen
ATE247483T1 (de) Matrixprotein enthaltende zusammensetzungen für entzündliche und infektiöse zustände
DE60027409D1 (de) Glykosylierte leptinzusammensetzungen und zugehörige verfahren
EP0888124A4 (de) Immunogene Zusammenstellungen von Porphyromonas Gingivalis Peptiden und derenVerfahren
PT1220685E (pt) Composicoes farmaceuticas de um agente fibrinolitico
ID25478A (id) Agonis 5-ht1f
ATE313628T1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
FR2747309B1 (fr) Nouvelles compositions destinees aux traitements des brulures et blessures, contenant differents acylaminoacides et lipoylaminoacides
WO1998021231A3 (en) Streptococcus uberis lactoferrin-binding protein
ATE318612T1 (de) Methoden und zusammensetzungen zur behandlung der hyperlipidämie

Legal Events

Date Code Title Description
8363 Opposition against the patent